The much awaited Facebook’s Oculus Rift virtual reality headgear seems to be on track for its consumer launch. The Oculus team announced on Monday that Rift SDK 1.0 is shipping this week to developers with early builds of final Rift hardware.
“The Rift SDK 1.0 and runtime include features tied to the consumer product, so we’ve currently limited the release to developers putting final touches on launch titles”, the blog post read.
Oculus VR founder Palmer Luckey tweeted that the manufacturing process is going well, and re-iterated that the headset is on track for its slated launch.
“Thrilled to share some news: Manufacturing continues to go well, and we are still on-target for an awesome Rift launch in Q1!” Luckey tweeted.
Although the price of the PC-based VR is not yet known, speculations suggest that it will cost more than $350, Gizmag reported. Also, earlier this year, Oculus revealed the recommended specs for the upcoming device, and it will require high-end parts like GPU and processor to maintain a consistent 90 fps while running two 1200x1080 displays.
“Preorders are coming soon after new year. Enjoy a stress-free holiday, we won’t launch preorders without warning!” Luckey tweeted.
Technology
Oculus Rift VR On Track For Q1 Launch, Pre-orders Coming Soon After New Year
The much awaited Facebook’s Oculus Rift virtual reality headgear seems to be on track for its consumer launch. The Oculus team announced on Monday that Rift SDK 1.0 is shipping this week to developers with early builds o…
1 min read
Related articles
Technology
CERN and Mistral AI Agree to Develop a Model for Collider Research
The proposed system would train on billions of simulated proton-proton events as the High-Luminosity Large Hadron Collider nears operation around 2030.
Technology
Huawei Proposes AI-Native Mobile Core to Coordinate Agent Tasks
The design adds a Data & AI Plane and three service concepts. Huawei forecasts that 900 billion AI agents could be served by 2035.
Health
FDA Clears SimBioSys Breast Cancer Recurrence Risk Software
The retrospective validation covered 2,129 patients. A separate 2026 ASCO abstract reported higher recurrence-free survival risk in patients above a prespecified score cutoff.


